Lyka Labs Limited
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-d… Read more
Lyka Labs Limited (LYKALABS) - Net Assets
Latest net assets as of September 2025: ₹1.01 Billion INR
Based on the latest financial reports, Lyka Labs Limited (LYKALABS) has net assets worth ₹1.01 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹1.68 Billion) and total liabilities (₹664.32 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹1.01 Billion |
| % of Total Assets | 60.41% |
| Annual Growth Rate | 6.64% |
| 5-Year Change | N/A |
| 10-Year Change | 110.73% |
| Growth Volatility | 75.15 |
Lyka Labs Limited - Net Assets Trend (2005–2025)
This chart illustrates how Lyka Labs Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lyka Labs Limited (2005–2025)
The table below shows the annual net assets of Lyka Labs Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹1.04 Billion | +51.73% |
| 2024-03-31 | ₹682.65 Million | +49.47% |
| 2023-03-31 | ₹456.71 Million | +238.53% |
| 2022-03-31 | ₹134.91 Million | +153.76% |
| 2021-03-31 | ₹-250.93 Million | -66.05% |
| 2020-03-31 | ₹-151.11 Million | -133.02% |
| 2019-03-31 | ₹457.59 Million | -21.43% |
| 2018-03-31 | ₹582.36 Million | +38.32% |
| 2017-03-31 | ₹421.01 Million | -14.35% |
| 2016-03-31 | ₹491.54 Million | +5.55% |
| 2015-03-31 | ₹465.71 Million | -16.86% |
| 2014-03-31 | ₹560.17 Million | -19.70% |
| 2013-03-31 | ₹697.62 Million | -7.69% |
| 2012-03-31 | ₹755.73 Million | -46.98% |
| 2010-03-31 | ₹1.43 Billion | +14.61% |
| 2009-03-31 | ₹1.24 Billion | +59.29% |
| 2008-03-31 | ₹780.73 Million | +69.45% |
| 2007-03-31 | ₹460.74 Million | +60.96% |
| 2005-03-31 | ₹286.25 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lyka Labs Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130135200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹356.90 Million | 34.47% |
| Other Comprehensive Income | ₹99.06 Million | 9.57% |
| Other Components | ₹1.88 Billion | 181.64% |
| Total Equity | ₹1.04 Billion | 100.00% |
Lyka Labs Limited Competitors by Market Cap
The table below lists competitors of Lyka Labs Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dome Gold Mines Ltd
AU:DME
|
$8.51 Million |
|
J.R.W. Utility Public Company Limited
BK:JR
|
$8.51 Million |
|
Power & Instrumental (Gujarat) Limited
NSE:PIGL
|
$8.52 Million |
|
Atlantic Sapphire ASA
OTCQB:AASZF
|
$8.52 Million |
|
Imago Mulia Persada Tbk PT
JK:LFLO
|
$8.51 Million |
|
Silla Textile Co.Ltd
KQ:001000
|
$8.50 Million |
|
Wiseway Group Ltd
AU:WWG
|
$8.50 Million |
|
Softing AG
XETRA:SYT
|
$8.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lyka Labs Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 681,543,000 to 1,035,502,000, a change of 353,959,000 (51.9%).
- Net income of 80,120,000 contributed positively to equity growth.
- Share repurchases of 272,025,000 reduced equity.
- New share issuances of 272,025,000 increased equity.
- Other comprehensive income decreased equity by 88,861,000.
- Other factors increased equity by 362,700,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹80.12 Million | +7.74% |
| Share Repurchases | ₹272.02 Million | -26.27% |
| Share Issuances | ₹272.02 Million | +26.27% |
| Other Comprehensive Income | ₹-88.86 Million | -8.58% |
| Other Changes | ₹362.70 Million | +35.03% |
| Total Change | ₹- | 51.93% |
Book Value vs Market Value Analysis
This analysis compares Lyka Labs Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.80x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 1.66x to 1.80x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹31.13 | ₹51.58 | x |
| 2007-03-31 | ₹33.04 | ₹51.58 | x |
| 2008-03-31 | ₹45.89 | ₹51.58 | x |
| 2009-03-31 | ₹71.92 | ₹51.58 | x |
| 2010-03-31 | ₹64.97 | ₹51.58 | x |
| 2012-03-31 | ₹34.23 | ₹51.58 | x |
| 2013-03-31 | ₹31.02 | ₹51.58 | x |
| 2014-03-31 | ₹24.43 | ₹51.58 | x |
| 2015-03-31 | ₹19.95 | ₹51.58 | x |
| 2016-03-31 | ₹-12.97 | ₹51.58 | x |
| 2017-03-31 | ₹17.79 | ₹51.58 | x |
| 2018-03-31 | ₹20.51 | ₹51.58 | x |
| 2019-03-31 | ₹15.73 | ₹51.58 | x |
| 2020-03-31 | ₹-5.03 | ₹51.58 | x |
| 2021-03-31 | ₹-8.99 | ₹51.58 | x |
| 2022-03-31 | ₹4.65 | ₹51.58 | x |
| 2023-03-31 | ₹15.79 | ₹51.58 | x |
| 2024-03-31 | ₹20.67 | ₹51.58 | x |
| 2025-03-31 | ₹28.69 | ₹51.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Lyka Labs Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.74%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.69%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 1.70x
- Recent ROE (7.74%) is below the historical average (8.39%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -1.76% | -1.10% | 0.33x | 4.90x | ₹-33.65 Million |
| 2007 | -24.52% | -14.52% | 0.49x | 3.47x | ₹-159.06 Million |
| 2008 | 5.37% | 4.67% | 0.49x | 2.36x | ₹-36.18 Million |
| 2009 | -3.97% | -2.97% | 0.54x | 2.48x | ₹-170.98 Million |
| 2010 | 1.72% | 1.73% | 0.39x | 2.54x | ₹-116.10 Million |
| 2012 | -0.66% | -0.45% | 0.38x | 3.82x | ₹-78.73 Million |
| 2013 | -1.06% | -0.56% | 0.44x | 4.32x | ₹-74.03 Million |
| 2014 | -12.50% | -5.54% | 0.36x | 6.25x | ₹-118.61 Million |
| 2015 | -11.49% | -2.98% | 0.60x | 6.47x | ₹-92.55 Million |
| 2016 | 0.00% | 2.89% | 0.53x | 0.00x | ₹65.85 Million |
| 2017 | -14.13% | -5.57% | 0.40x | 6.34x | ₹-94.59 Million |
| 2018 | -32.60% | -30.65% | 0.24x | 4.44x | ₹-225.75 Million |
| 2019 | -12.39% | -8.64% | 0.30x | 4.85x | ₹-100.32 Million |
| 2020 | 0.00% | -109.27% | 0.28x | 0.00x | ₹-591.07 Million |
| 2021 | 0.00% | -17.22% | 0.35x | 0.00x | ₹-89.75 Million |
| 2022 | 292.39% | 21.24% | 0.99x | 13.92x | ₹376.66 Million |
| 2023 | -29.08% | -14.41% | 0.61x | 3.33x | ₹-177.56 Million |
| 2024 | -3.65% | -2.37% | 0.67x | 2.30x | ₹-93.05 Million |
| 2025 | 7.74% | 5.69% | 0.80x | 1.70x | ₹-23.43 Million |
Industry Comparison
This section compares Lyka Labs Limited's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $16,263,523,767
- Average return on equity (ROE) among peers: -3.62%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lyka Labs Limited (LYKALABS) | ₹1.01 Billion | -1.76% | 0.66x | $8.51 Million |
| Anthem Biosciences Ltd (ANTHEM) | $17.41 Billion | 22.13% | 0.16x | $17.29 Million |
| BALAXI PHARMACEUTICALS LIMITED (BALAXI) | $15.55 Million | -49.65% | 0.08x | $10.46 Million |
| Biocon Limited (BIOCON) | $14.77 Billion | 31.41% | 0.41x | $2.54 Billion |
| Blue Jet Healthcare Limited (BLUEJET) | $8.45 Billion | 19.37% | 0.25x | $134.93 Million |
| Concord Biotech Limited (CONCORDBIO) | $18.13 Billion | 20.50% | 0.12x | $346.78 Million |
| Dishman Carbogen Amcis Limited (DCAL) | $9.29 Billion | 6.11% | 1.42x | $103.76 Million |
| Haleos Labs Limited (HALEOSLABS) | $1.06 Billion | 16.78% | 1.56x | $129.20K |
| ONESOURCE SPECIALTY PHARMA LTD (ONESOURCE) | $75.29 Billion | 0.00% | 0.00x | $1.21 Billion |
| Panacea Biotec Limited (PANACEABIO) | $1.96 Billion | -99.24% | 6.10x | $56.46 Million |